[Bone and myeloma].
Osteolysis induced by medullary plasmocyte proliferation is related to an increase in the number of osteoclasts in contact with myeloma cells. Osteoclast activating factors (OAF), notably lymphokines such as IL-1 beta, and IL-6, or tumour necrosis factor (TNF), produced by plasmocytes or their microenvironment, have been demonstrated. Bisphosphonates, which are potent anti-osteoclastic agents, are effective during episodes of hypercalcaemia. Their ability to delay the progression of osteolysis is being evaluated.
Ravaud
P
P
Clinique de rhumatologie, hôpital Cochin, Paris.
Roux
C
C
D001847:Bone Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications*; D010014:Osteolysis / Q000188:drug therapy / Q000209:etiology; D011859:Radiography
D004164:Diphosphonates
Os et myélome.